A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

  • STATUS
    Recruiting
  • End date
    Jul 26, 2024
  • participants needed
    170
  • sponsor
    Bayer
Updated on 21 June 2021
Investigator
Bayer Clinical Trials Contact
Primary Contact
Prince of Wales Hospital (0.0 mi away) Contact
+78 other location
cancer
kidney function tests
experimental drug
primary tumor
brain metastases
solid tumor
NTRK
renal function tests
fibrosarcoma
kidney function test

Summary

This research study is done to test the safety of the new drug selitrectinib in children and adults with cancer having a change in a particular gene (NTRK1, NTRK2 or NTRK3). The drug may treat cancer by interfering with the effect of the NTRK genes on cancer growth. The study also investigates how the drug is absorbed and processed in the human body, and how well and for how long the cancer responds to the drug. This is the first study to test selitrectinib in humans with cancer, for whom no other effective therapy exists.

Description

The trial will be conducted in 2 parts: dose escalation and expansion (Phase 1) and Phase 2.

The primary objective of Phase 1 is to establish the recommended dose of selitrectinib to treat neurotrophic tyrosine kinase (NTRK) fusion cancers in patients a) aged 12 years and older and b) younger than 12 years. Secondary objectives of Phase 1 are to characterize the pharmakokinetic properties of the test drug, its safety and tolerability, and to assess the objective response rate (ORR) of NTRK-tumors.

The primary objective of Phase 2 is to assess the overall response rate in NTRK fusion cancer patients as determined by an independent radiology committee (IRR). Secondary objectives of Phase 2 comprise the safety and efficacy of selitrectinib at the recommended dose.

Details
Condition Pancreatic Cancer, Fibrosarcoma, Bronchogenic Carcinoma, Non-Small Cell Lung Cancer, Bile duct carcinoma, Intestinal Cancer, Colorectal Cancer, Mesoblastic Nephroma, Cholangiocarcinoma, Astrocytoma, Invasive Ductal Breast Carcinoma, Thyroid Adenoma, Uterine Cancer, Central Nervous System Neoplasms, Respiratory Tract Neoplasm, Thoracic Neoplasms, Biliary neoplasm, Ovarian Cancer, Nerve Sheath Tumors, Glioblastoma Multiforme, Nevi and Melanomas, melanoma, Renal Cell Carcinoma, gliomas pontine, Lung Neoplasm, skin cancer, Malignant neoplasm of brain, Sarcoma, Bronchial Neoplasm, gastrointestinal stromal tumor, salivary gland cancer, Neoplasms, Nerve Tissue, Metastatic Melanoma, Colon Cancer Screening, Brain Tumor (Pediatric), Colon cancer; rectal cancer, Head and Neck Squamous Cell Carcinoma, Skin Carcinoma, Recurrent Ovarian Cancer, Urothelial Tract Cancer, Sarcoma (Pediatric), Islet Ce417ll Cancer, Infantile Fibrosarcoma, Breast Secretory Carcinoma, Lung Cancer, Brain Cancer, Malignant Melanoma, Biliary Tract Cancer, Brain Tumor, Thyroid Cancer, Renal Cell Cancer, Soft Tissue Sarcoma, Solid Tumors Harboring NTRK Fusion
Treatment LOXO-195, BAY2731954, Selitrectinib (BAY2731954)
Clinical Study IdentifierNCT03215511
SponsorBayer
Last Modified on21 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Advanced solid tumor for which, in the opinion of the investigator, no other standard therapy offers greater benefit
A solid tumor diagnosis in the setting of
a) a documented NTRK fusion and a clinical history of relapse following a response to a prior TRK inhibitor
b) a documented NTRK fusion unresponsive to a prior TRK inhibitor
c) a documented NTRK fusion and a clinical history of intolerance to a prior TRK inhibitor
NTRK gene fusions will be identified in a CLIA-certified (or equivalently-accredited diagnostic) laboratory. If such a report cannot be provided, other available certifications/accreditations are required and need to be documented. Patients with infantile fibrosarcoma (IFS) or congenital mesoblastic nephroma (CMN) may be enrolled based on an ETV6+ FISH test without identifying NTRK3
Performance Status: Eastern Cooperative Oncology Group (ECOG) score 2 in adults or Karnofsky Performance Score (KPS) Score50% (age 16 years) or Lansky Performance Score (LPS) 40% (age < 16 years)
Life expectancy of at least 3 months
Adequate hematologic, hepatic and renal function
Patients with stable central nervous system (CNS) primary tumor, brain metastases, or treated spinal cord compression are eligible if neurological symptoms have been stable for 7 days prior to the first dose of selitrectinib
Ability to receive study drug orally or by enteral administration

Exclusion Criteria

Prior exposure to second generation TRK inhibitor (e.g. selitrectinib, repotrectinib (TPX-0005)), taletrectinib (DS-6501b/AB-106)). Exception is in case patient presented intolerance to the second generation TRK inhibitor agent and the duration of exposure was less than 28 days. No previous treatment with selitrectinib is allowed
Concurrent treatment with a strong CYP3A4 inhibitor or inducer, consumption of grapefruit juice or Seville oranges, or drugs associated with QT prolongation
Clinically significant active cardiovascular disease or history of myocardial infarction within 3 months prior to planned start of selitrectinib, or prolongation of QT interval corrected for heart rate (QTc interval) >480 milliseconds within past 6 months
Major surgery within 7 days of enrollment
Uncontrolled systemic bacterial, fungal or viral infection
Pregnancy or lactation
Known hypersensitivity to selitrectinib or Ora-Sweet SF and OraPlus for patients receiving liquid formulation
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note